Syndesi Therapeutics ^Companies

Syndesi Therapeutics is a pharmaceutical company focused on developing a drug candidate for the treatment of cognitive disorders associated with neurological conditions. Their main goal is to develop molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission in the brain. By regulating synaptic transmission, Syndesi aims to provide a promising approach to treating disorders like Alzheimer's Disease that are characterized by cognitive impairment. The company has an exclusive license to its platform technology from UCB, a leading company in SV2A research, which highlights their expertise and potential for success in this field.